结节性皮肤炎疫苗市场规模、份额和成长分析：按疫苗类型、给药途径、目标动物、最终用户和地区划分－2026-2033年产业预测

2024年全球结节性皮斑病疫苗市场价值为27亿美元，预计2025年将成长至28.4亿美元，到2033年将成长至41.9亿美元。预测期（2026-2033年）的复合年增长率预计为5.0%。

全球结节性皮癣菌疫苗市场的主要驱动力是牛中该疾病发病率的上升和地理范围的扩大，这促使人们需要加强预防措施和疫苗接种。该市场涵盖多种疫苗类型，例如活病毒疫苗疫苗和灭活疫苗，以及大规模免疫宣传活动的物流和服务支援。疫情爆发会导致严重的生产损失、贸易限制和动物福利问题。从区域性应变转向跨区域协调免疫接种，促使亚洲和欧洲等地区加强监测系统建置和改善低温运输物流。製造商正在投资研发耐热的单剂量製剂，以简化现场接种流程。人工智慧技术进一步优化了监测和分发，提高了检测效率，并确保及时接种疫苗，最终推动了市场成长。

推动全球结节性皮肤病疫苗市场发展的因素

结节性皮癣菌疫苗的需求主要受流行地区扩大免疫宣传活动的推动。这些努力有助于有效分配资源，提高兽医服务的参与度，并优先考虑牛的免疫接种，从而提高疫苗接种率。政府和援助组织的支持在加强低温运输基础设施、发展人力资源和改善推广活动方面发挥着至关重要的作用，有助于将疫苗广泛分发给农民。精简的物流和有组织的群体免疫接种活动有助于消除获取障碍，增强人们对免疫接种效果的信心，最终促进公共和私营部门持续开展宣传活动运动并签订采购合约。反过来，这又促进了市场的可持续成长，并鼓励生产者提高产能。

全球皮肤结节疫苗市场的限制因素

监管核准的复杂性和延误给新型结节性皮肤病疫苗的及时上市带来了重大挑战。这些复杂性延长了评估週期，并为研发人员带来了不确定性。此外，各国不同的註册要求和申请预期可能需要进行广泛的实地调查并收集更多数据，这增加了资源需求，并可能对中小型生产者造成阻碍。漫长的核准流程也会进一步阻碍疫苗采购和接种计画的实施，削弱疫苗上市的势头，并限制生产商的获利能力。这种不确定性会抑制研发投入，导致改良疫苗无法及时送达受影响最严重的地区。

结节性皮肤病疫苗的全球市场趋势

全球结节性皮癣菌疫苗市场正呈现显着的在地化生产能力提升趋势。生产商优先考虑在疫区附近建造生产设施，以提高应对力和供应链韧性。这一策略转变不仅减少了对远端供应商的依赖，也促进了与当地企业和政府的合作。透过投资技术转移和人力资源开发，企业能够有效率地扩大疫苗生产规模，适应区域病原菌株的特性，并应对不同的监管环境。这些努力正在推动兽医服务领域的疫苗应用，并透过在市场中创造本地化价值来促进永续成长。

目录

介绍

• 调查目的
• 市场定义和范围

调查方法

• 研究过程
• 二级资料和一级资料的方法
• 市场规模估算方法

执行摘要

• 全球市场展望
• 市场主要亮点
• 细分市场概览
• 竞争环境概述

市场动态及展望

• 总体经济指标
• 促进者和机会
• 抑制因素和挑战
• 供给面趋势
• 需求面趋势
• 波特的分析和影响

市场考察

• 关键成功因素
• 影响市场的因素
• 主要投资机会
• 生态系测绘
• 2025年市场吸引力指数
• PESTEL 分析
• 监理情势

全球结节性皮斑病疫苗市场规模：按疫苗类型和复合年增长率划分（2026-2033 年）

• 减毒活病毒疫苗
• 灭活疫苗
• 重组疫苗

全球结节性皮斑病疫苗市场规模：依给药途径及复合年增长率划分（2026-2033 年）

• 肌肉内注射
• 皮下注射
• 口服

全球结节性皮癣菌疫苗市场规模：按目标动物和复合年增长率 (2026-2033) 划分

• 牛
• 水牛
• 其他的

全球结节性皮斑病疫苗市场规模：按最终用户和复合年增长率划分（2026-2033 年）

• 动物医院
• 畜牧业的棋子
• 研究机构

结节性皮肤增生疫苗的全球市场规模和复合年增长率（2026-2033）

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场公司采取的策略
• 近期市场趋势
• 企业市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 按细分市场进行企业市占率分析
  • 2023-2025年营收年比比较

主要企业简介

• Zoetis
• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Virbac
• Ceva Sante Animale
• Oxford Immunotec
• Vetoquinol
• Huvepharma
• iO Veterinary
• Algenex
• MSD Animal Health
• AgriLabs
• Intervet
• Bioniche Animal Health
• KindredBio
• Indian Immunologicals Ltd.
• Adimmune Corporation
• Biovac
• Kye Pharmaceuticals

结论与建议

Global Lumpy Skin Disease Vaccines Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.84 Billion in 2025 to USD 4.19 Billion by 2033, growing at a CAGR of 5.0% during the forecast period (2026-2033).

The global market for lumpy skin disease vaccines is primarily driven by the increasing incidence and geographic spread of outbreaks among cattle, necessitating enhanced preventive measures and vaccination responses. This market includes various vaccine types such as live attenuated and inactivated formulations alongside logistical and service support for mass immunization campaigns. Outbreaks lead to substantial production losses, trade restrictions, and animal welfare issues. The evolution from localized responses to coordinated transregional vaccination efforts illustrates growing efforts in regions like Asia and Europe, with a focus on enhanced surveillance and improved cold chain logistics. Manufacturers are investing in thermostable, single-dose formulations for simpler field deployment. AI technology is further optimizing surveillance and distribution, enhancing detection efficiency, and ensuring timely vaccination, ultimately facilitating market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Lumpy Skin Disease Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Lumpy Skin Disease Vaccines Market Segments Analysis

Global lumpy skin disease vaccines market is segmented by vaccine type, administration route, target animal, end-user and region. Based on vaccine type, the market is segmented into Live Attenuated Vaccines, Inactivated Vaccines and Recombinant Vaccines. Based on administration route, the market is segmented into Intramuscular, Subcutaneous and Oral. Based on target animal, the market is segmented into Cattle, Buffalo and Others. Based on end-user, the market is segmented into Veterinary Clinics, Livestock Farmers and Research Institutions. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Lumpy Skin Disease Vaccines Market

The demand for lumpy skin disease vaccines is significantly driven by the expansion of vaccination campaigns in regions where the disease is endemic. These initiatives effectively coordinate resources, involve veterinary services, and prioritize the immunization of cattle, leading to increased vaccine uptake. Support from governments and donors plays a crucial role in enhancing cold chain infrastructure, training personnel, and improving outreach, which facilitates wider distribution of vaccines to farmers. Streamlined logistics and organized mass vaccination efforts help eliminate access barriers and foster trust in vaccination results, ultimately encouraging repeat campaigns and procurement commitments from both public and private sectors, thus promoting ongoing market growth and motivating manufacturers to enhance production capacities.

Restraints in the Global Lumpy Skin Disease Vaccines Market

The complexities and delays associated with regulatory approvals pose significant challenges to the timely introduction of new lumpy skin disease vaccines. These intricacies extend evaluation periods and create uncertainty for developers. Additionally, varying national registration requirements and differing dossier expectations demand extensive local studies or supplementary data, which increases resource demands and can deter smaller manufacturers. Protracted authorization processes further hinder procurement and the implementation of vaccination programs, diminishing the momentum for adoption and restricting manufacturers' revenue potential. Such uncertainty may discourage investment in research and development, consequently delaying the availability of enhanced vaccines to the regions most impacted.

Market Trends of the Global Lumpy Skin Disease Vaccines Market

The Global Lumpy Skin Disease Vaccines market is witnessing a notable trend towards localized manufacturing capacity. As manufacturers seek to enhance their responsiveness and supply chain resilience, they are prioritizing production facilities closer to affected regions. This strategic shift not only reduces reliance on distant suppliers but also fosters collaborations with local firms and governments. By investing in technology transfer and workforce development, companies are scaling vaccine production efficiently, addressing regional strain profiles, and navigating varied regulatory landscapes. These initiatives are driving adoption among veterinary services and promoting sustainable growth through localized value creation in the market.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Lumpy Skin Disease Vaccines Market Size by Vaccine Type & CAGR (2026-2033)

• Market Overview
• Live Attenuated Vaccines
• Inactivated Vaccines
• Recombinant Vaccines

Global Lumpy Skin Disease Vaccines Market Size by Administration Route & CAGR (2026-2033)

• Market Overview
• Intramuscular
• Subcutaneous
• Oral

Global Lumpy Skin Disease Vaccines Market Size by Target Animal & CAGR (2026-2033)

• Market Overview
• Cattle
• Buffalo
• Others

Global Lumpy Skin Disease Vaccines Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Veterinary Clinics
• Livestock Farmers
• Research Institutions

Global Lumpy Skin Disease Vaccines Market Size & CAGR (2026-2033)

• North America (Vaccine Type, Administration Route, Target Animal, End-User)
  • US
  • Canada
• Europe (Vaccine Type, Administration Route, Target Animal, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Vaccine Type, Administration Route, Target Animal, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Vaccine Type, Administration Route, Target Animal, End-User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Vaccine Type, Administration Route, Target Animal, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Zoetis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oxford Immunotec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Huvepharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• iO Veterinary
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Algenex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AgriLabs
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intervet
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioniche Animal Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KindredBio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Indian Immunologicals Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adimmune Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biovac
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kye Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations